Related Experiment Video

Updated: Jul 7, 2026

Kinase Inhibitor Screening In Self-assembled Human Protein Microarrays
13:22

Kinase Inhibitor Screening In Self-assembled Human Protein Microarrays

Published on: October 23, 2019

Clinical potential of targeting Bruton's tyrosine kinase

Fatih M Uckun1

  • 1Parker Hughes Cancer Center, Roseville, Minnesota 55113, USA.

International Reviews of Immunology
|February 27, 2008
PubMed

Insights

Bruton

Area of Science:

  • Oncology
  • Immunology
  • Hematology

Background:

  • Bruton's tyrosine kinase (BTK) plays a crucial role in B-cell development and signaling.
  • BTK's antiapoptotic function contributes to cancer cell survival in BTK-expressing malignancies.
  • Cancer patients face an elevated risk of thromboembolic complications, necessitating antithrombotic strategies.

Purpose of the Study:

  • To review the multifaceted role of BTK in cancer drug resistance.
  • To explore the significance of BTK in thromboembolism.
  • To examine BTK's involvement in pathological immune responses, including graft-versus-host disease.

Main Methods:

  • Literature review focusing on the biological activity and therapeutic potential of BTK inhibitors.
  • Analysis of the role of BTK in cancer cell survival and drug resistance mechanisms.
  • Examination of the antithrombotic properties of BTK inhibitors and their clinical relevance.

Main Results:

  • BTK inhibition demonstrates potential in overcoming drug resistance in certain cancers.
  • BTK inhibitors possess inherent antithrombotic effects, beneficial for cancer patients.
  • BTK is implicated in various immune responses, suggesting broader therapeutic applications.

Conclusions:

  • Targeting BTK offers a promising therapeutic strategy for BTK-expressing malignancies.
  • The dual action of BTK inhibitors in combating cancer and preventing thrombosis is significant.
  • Further research into BTK inhibition for immune-related disorders like graft-versus-host disease is warranted.

More Related Videos

Pre-clinical Evaluation of Tyrosine Kinase Inhibitors for Treatment of Acute Leukemia10:49

Pre-clinical Evaluation of Tyrosine Kinase Inhibitors for Treatment of Acute Leukemia

Published on: September 18, 2013

Assessment of Resistance to Tyrosine Kinase Inhibitors by an Interrogation of Signal Transduction Pathways by Antibody Arrays07:42

Assessment of Resistance to Tyrosine Kinase Inhibitors by an Interrogation of Signal Transduction Pathways by Antibody Arrays

Published on: September 19, 2018

Related Concept Videos

Targeted Cancer Therapies02:57

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against specific...
Targeted Cancer Therapies02:57

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against specific...
Transducer Mechanism: Enzyme-Linked Receptors01:27

Transducer Mechanism: Enzyme-Linked Receptors

Enzyme-linked receptors are cell-surface receptors acting as an enzyme or associating with an enzyme intracellularly. They make excellent drug targets. Drugs can bind to the extracellular ligand-binding domain or directly affect their enzymatic domain and alter their activity.
Major types that are helpful drug targets include:
Pharmacogenetics of Drug Targets: β₂-Adrenergic Receptors, Apo E, Thymidylate Synthase01:11

Pharmacogenetics of Drug Targets: β₂-Adrenergic Receptors, Apo E, Thymidylate Synthase

Genetic polymorphisms in drug targets have emerged as critical determinants of interindividual variability in drug response and toxicity. Pharmacogenomic investigations increasingly focus on identifying these variations to personalize and optimize therapeutic interventions. A drug target may be a receptor, enzyme, or signaling protein involved in pharmacologic responses or disease-related pathways. While early pharmacogenetic studies focused primarily on drug metabolism, current research...
Receptor Tyrosine Kinases01:26

Receptor Tyrosine Kinases

Receptor tyrosine kinases or RTKs are membrane-bound receptors that phosphorylate specific tyrosine on protein substrates. RTKs regulate cellular growth, differentiation, survival, and migration. They contain an extracellular ligand binding domain, a transmembrane domain, and a cytosolic tail with intrinsic kinase activity. Several extracellular signaling molecules activate RTKs in one or more ways and relay the signal downstream. Ligands such as platelet-derived growth factor (PDGF) or...
Mitogens and the Cell Cycle02:38

Mitogens and the Cell Cycle

Mitogens and their receptors play a crucial role in controlling the progression of the cell cycle. However, the loss of mitogenic control over cell division leads to tumor formation. Therefore, mitogens and mitogen receptors play an important role in cancer research. For instance, the epidermal growth factor (EGF) - a type of mitogen and its transmembrane receptor (EGFR), decides the fate of the cell's proliferation. When EGF binds to EGFR, a member of the ErbB family of tyrosine kinase...